Ovarian cancer has become the largest cause of gynaecological cancer-related mortality. It
is typically diagnosed at a late stage and has no effective screening strategy. Ovarian cancer …

Ovarian cancer (OC) is the most lethal gynaecological malignancy. The search for a widely
affordable and accessible screening strategy to reduce mortality from OC is still ongoing …

Nonepithelial ovarian cancers (NEOC) are a group of rare malignancies, including germ cell
tumours (GCT) and sex cord-stromal tumours (SCST), along with small-cell carcinomas and …

As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and
breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment …

Background Cuproptosis, an emerging form of programmed cell death, has recently been
identified. However, the association between cuproptosis-related long non-coding RNA …

Simple Summary Ovarian cancer has the highest mortality rate of any type of gynecological
cancer because it is diagnosed in advanced stages and its recurrence rate is about 80 …

Gynecologic cancer, which includes ovarian, cervical, endometrial, vulvar, and vaginal
cancer, is a major health concern for women all over the world. Despite the availability of …

Pancreatic cancer (PC) is characterized by (epi) genetic and microenvironmental alterations
that negatively impact the treatment outcomes. New targeted therapies have been pursued …

Purpose The addition of PARP inhibitors to chemotherapy has been assessed in> 80 clinical
trials across multiple malignancies, on the premise that PARP inhibitors will increase …

Background PARP inhibitors (PARPi) have revolutionized the management of advanced
ovarian carcinoma, and were investigated as forefront treatment in recurrent disease. The …